IMMP News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

IM

Volume

11.74K

Loading chart

IM

IMMPImmutep Limited American Depositary Shares

IMMP

Pay with—

Available Balance0.00

IM

Mkt Cap

$24.9M

Volume

11.74K

Next Earnings

N/A

Chart Earnings News About Insider Filings

Head and Neck Squamous Cell Carcinoma (HNSCC) - Market Insights, Epidemiology, and Market Forecast - 2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape CareThe HNSCC market is projected to grow from $850 million in 2025 to $2.56 billion by 2036 (10.5% CAGR), driven by HPV-targeted vaccines, checkpoint inhibitors, and biomarker-led patient selection. The US will remain the largest market at $2.082 billion. Key therapies include KEYTRUDA and OPDIVO, with emerging candidates like petosemtamab and amivantamab showing promise in clinical development.GlobeNewswire Inc. · Sep 30, 2026

Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsightThe head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a 10.5% CAGR from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the highest revenue among HNSCC therapies.GlobeNewswire Inc. · Jul 21, 2026

Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsightThe head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a CAGR of 10.5% from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the highest revenue. Multiple companies are advancing innovative therapies targeting HPV16-positive HNSCC and other molecular pathways.GlobeNewswire Inc. · Jul 13, 2026

Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Graphic Packaging Holding Company (GPK), Immutep Limited (IMMP), and Phreesia, Inc. (PHR) Announced by Holzer & Holzer, LLCHolzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against Graphic Packaging Holding Company, Immutep Limited, and Phreesia, Inc. The lawsuits allege materially false statements and/or failure to disclose material facts regarding inventory management, clinical trial status, and long-term growth outlook respectively. Investors who purchased shares during specified periods and suffered losses are encouraged to seek lead plaintiff status by the July 6-13, 2026 deadlines.GlobeNewswire Inc. · Jul 1, 2026

Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Graphic Packaging Holding Company (GPK), Immutep Limited (IMMP), and Phreesia, Inc. (PHR) Announced by Holzer & Holzer, LLCHolzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against multiple companies including Graphic Packaging Holding Company, Immutep Limited, and Phreesia, Inc. The lawsuits allege materially false or misleading statements regarding inventory management, clinical trial prospects, and growth outlook respectively. Investors who purchased shares during specified periods and suffered losses are encouraged to seek lead plaintiff status.GlobeNewswire Inc. · Jun 29, 2026

Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor HarmA class action lawsuit has been filed against Immutep Limited alleging that company defendants made materially false and misleading statements regarding the TACTI-004 trial's status and prospects. The complaint claims defendants concealed negative clinical data and misrepresented the trial's operational progress and interim futility analysis timing. Investors who purchased Immutep securities between March 24, 2025 and March 12, 2026 are eligible to join the case, with a lead plaintiff deadline of July 6, 2026.GlobeNewswire Inc. · Jun 14, 2026

IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law FirmThe Schall Law Firm is seeking investors to join a class action lawsuit against Immutep Limited for securities fraud. The company allegedly made false and misleading statements about its TACTI-004 trial results, claiming 'strong operational progress' while knowing the trial would fail to meet its primary efficacy endpoints. Investors who purchased securities between March 24, 2025 and March 12, 2026 are encouraged to participate.GlobeNewswire Inc. · Jun 12, 2026

IMMP UPCOMING DEADLINE: Levi & Korsinsky Alerts Immutep Limited Stockholders of Securities Class Action - Contact the FirmImmutep Limited (IMMP) stockholders who purchased ADRs between March 24, 2025 and March 12, 2026 have until July 6, 2026 to seek lead plaintiff appointment in a securities class action. The lawsuit follows an 83% single-day stock decline after the company disclosed on March 13, 2026 that an Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III trial for futility.GlobeNewswire Inc. · Jun 8, 2026

Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Graphic Packaging Holding Company (GPK), Immutep Limited (IMMP), and Phreesia, Inc. (PHR) Announced by Holzer & Holzer, LLCHolzer & Holzer, LLC announced lead plaintiff deadlines for multiple shareholder class action lawsuits against companies including Graphic Packaging Holding Company, Immutep Limited, and Phreesia, Inc. The lawsuits allege materially false and misleading statements regarding inventory management, clinical trial prospects, and growth outlook. Investors who purchased shares during specified periods and suffered losses are encouraged to seek lead plaintiff status by the announced deadlines in July 2026.GlobeNewswire Inc. · Jun 8, 2026

Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor HarmA class action lawsuit has been filed against Immutep Limited (NASDAQ: IMMP) alleging that company defendants made materially false and misleading statements regarding the TACTI-004 trial's status and prospects. The complaint claims defendants concealed negative clinical data while misrepresenting the trial's operational progress and efficacy prospects. Investors who purchased Immutep securities between March 24, 2025 and March 12, 2026 are eligible to join the case, with a lead plaintiff deadline of July 6, 2026.GlobeNewswire Inc. · Jun 7, 2026

to start trading

IM

IMMPImmutep Limited American Depositary Shares

IMMP

Pay with—

Available Balance0.00

Your PositionYou don't own any IMMP yet.

Related Tickers

Earnings